Joanne Carson
YOU?
Author Swipe
View article: The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025
The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025 Open
Objectives To quantify population-level trends in publicly subsidised and private access of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in Australia. Design Longitudinal descriptive study using routinely collected data. Setting Na…
View article: Development of a machine learning model to predict short duration HCV treatment response
Development of a machine learning model to predict short duration HCV treatment response Open
Background Standard durations of direct acting antivirals (DAAs; 8–12 weeks) can be a barrier to HCV treatment initiation and completion among marginalised populations. This study developed a machine learning model to predict short-duratio…
View article: The costs and benefits of a prison needle and syringe program in Australia, 2025–30: a modelling study
The costs and benefits of a prison needle and syringe program in Australia, 2025–30: a modelling study Open
Objectives To estimate and compare the costs and benefits of introducing a prison needle and syringe program in all Australian prisons. Study design Stochastic compartmental modelling study. Setting All Australian prisons, 1 January 2010 t…
View article: Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With <scp>HIV</scp>: Findings From an International Cohort
Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With <span>HIV</span>: Findings From an International Cohort Open
Background Historically, hepatitis C virus (HCV) was difficult to treat among people with HIV. However, treatment with direct‐acting antivirals (DAAs) results in 90%–95% of people being cured. There is a need to understand why a proportion…
View article: Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014–2023)
Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014–2023) Open
Background Approximately 10% of people with HIV in Australia had active hepatitis C virus (HCV) infection prior to availability of government-subsidized direct-acting antiviral (DAA) therapy in 2016. This analysis evaluated progress toward…
View article: Contribution of prison-based hepatitis C treatment initiations to overall treatment uptake in Victoria, Australia
Contribution of prison-based hepatitis C treatment initiations to overall treatment uptake in Victoria, Australia Open
Australia has committed to WHO goals to eliminate hepatitis C virus (HCV) as a public health threat by 2030.1World Health OrganizationGlobal health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infection…
View article: Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) Open
Key Features: - The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) is a multinational consortium of longitudinal cohorts of people with HIV who are at risk of hepatitis C virus (HCV) infection or infected w…
View article: Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study
Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study Open
People in prison are at high risk of HCV given high injecting drug use prevalence. This study evaluated HCV incidence and associated injecting drug use characteristics in prison. The SToP‐C study enrolled people incarcerated in four Austra…
View article: Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study
Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study Open
We assessed the predictive capacity of the HCV-MOSAIC risk score, originally developed for primary early HCV infection, as a screening tool for HCV reinfection in 103 men who have sex with men (MSM) with HIV using data from the MOSAIC coho…
View article: Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study Open
Introduction Exploration of sexual and drug use behaviours following treatment for recent hepatitis C virus (HCV) is limited. This analysis modelled behavioural trajectories following treatment for recent HCV and assessed reinfection. Meth…
View article: Reinfection incidence and risk among people treated for recent hepatitis C virus infection
Reinfection incidence and risk among people treated for recent hepatitis C virus infection Open
Objective: Reinfection poses a challenge to hepatitis C virus (HCV) elimination. This analysis assessed incidence of, and factors associated with reinfection among people treated for recent HCV (duration of infection <12 months). Methods: …
View article: Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis
Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis Open
National Health and Medical Research Council.
View article: Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021
Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021 Open
Background: Direct-acting antiviral (DAA) treatment discontinuation may negatively impact HCV elimination efforts. In Australia, DAA therapy is pharmacy dispensed, generally in 4-week amounts, with the approved duration (8–24 wk) and volum…
View article: Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston
Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston Open
Background People experiencing homelessness are disproportionately affected by hepatitis C virus (HCV) infection compared with housed populations. Surveillance for HCV reinfection after successful treatment is a critical step in the care c…
View article: Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C)
Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C) Open
Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of hepatitis C virus (HCV) infection. This study assessed the effectiveness of direct‐acting antiviral (DAA) therapy among Aboriginal peoples in the three y…
View article: National trends in retreatment of HCV due to reinfection or treatment failure in Australia
National trends in retreatment of HCV due to reinfection or treatment failure in Australia Open
View article: Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct‐acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct‐acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort Open
Background and Aims In moving towards the elimination of hepatitis C virus (HCV) infection among people living with HIV, understanding HCV transmission patterns may provide insights to guide and evaluate interventions. In this study, we ev…
View article: Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The <scp>REACH‐C</scp> cohort
Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The <span>REACH‐C</span> cohort Open
Virological failure occurs in a small proportion of people treated for hepatitis C virus (HCV) with direct‐acting antiviral (DAA) therapies. This study assessed retreatment for virological failure in a large real‐world cohort. REACH‐C is a…
View article: Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis
Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis Open
View article: Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis
Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis Open
View article: High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study
High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study Open
Australia was one of the first countries with unrestricted access to government subsidized direct‐acting antiviral (DAA) therapy for adults with chronic hepatitis C virus. This study assessed real‐world DAA treatment outcomes across a dive…